Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Dr John LaMattina Joins Ziarco as Strategic Advisor

Published: Tuesday, March 19, 2013
Last Updated: Tuesday, March 19, 2013
Bookmark and Share
Dr LaMattina will provide input on the company's corporate, R&D strategy and growth plans.

Ziarco has appointed pharma leader and former President of Pfizer Global R&D, Dr John L. LaMattina as Strategic Advisor. His role at Ziarco will be to provide input on the company's corporate, R&D strategy and growth plans.

Commenting on his appointment, Dr LaMattina said: "Ziarco has amassed an excellent portfolio of early drug candidates with great potential. I am very much looking forward to working with the Ziarco team to convert these assets into valued new medicines."

Ziarco’s CEO, Dr Mike Yeadon, commented: "We are delighted that John is joining the team as a Strategic Advisor. Under his inspirational leadership during his long career at Pfizer, not only were several excellent medicines discovered and developed, but many of what are now industry-recognized R&D best-practises were established, as were many future leaders also. His expertise will be invaluable to use as we drive our portfolio of preclinical and clinical programs forward."

John L. LaMattina, PhD
Dr. LaMattina is a Senior Partner at PureTech and was previously President, Pfizer Global Research and Development and Senior Vice President, Pfizer Inc.

During Dr. LaMattina’s leadership tenure Pfizer advanced a number of important new medicines including Chantix, Selzentry, Lyrica, Inlyta, Xalkori and Xaljenz.

He is the author of numerous scientific publications and U.S. patents. In addition, Dr. LaMattina is the author of “Drug Truths: Dispelling the Myths About Pharma R&D” and “Devalued & Distrusted - Can the pharma industry restore its broken image.”

Dr. LaMattina serves on the Board of Directors of Ligand Pharmaceuticals, Vedanta and Gelesis, and is a member of the Scientific Advisory Board of Trevena Pharmaceuticals.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos